Li Dongjiu

Mr. Li Dongjiu, aged 57, is a non-executive director of the Company. Mr. Li has over 34 years of working experience in the pharmaceutical industry, over 29 years of which relates to management experience in the pharmaceutical and healthcare products industry. Mr. Li is a professor–level senior engineer and Doctor of engineering. Mr. Li obtained a bachelor’s degree in chemical engineering from Dalian University of Technology in July 1987, a master’s degree in management science and engineering from Wuhan Transportation University in July 1998, a master’s degree of arts in international economic and trade relations from the Flinders University of South Australia in October 2005, a PhD degree of transportation planning and management from Wuhan University of Technology in June 2013 and an EMBA degree from China Europe International Business School. Mr. Li held senior management positions in North China Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600812) from July 1987 to December 2009, successively as a general manager of Sales Company of North China Pharmaceutical Group Corporation, a general manager of Business Department of North China Pharmaceutical Group Corporation and deputy general manager of North China Pharmaceutical Co., Ltd. and the head of its financial department. Mr. Li joined Fosun Pharma Group for the first time in December 2009 and successively served as the president of Shanghai Fosun Pharmaceutical Development Co., Ltd., the chairman of the Commercialization and Consumer Products Management Committee of Fosun Pharmaceutical and the senior vice president of Fosun Pharmaceutical and also served as the director of Nature’s Sunshine Products Inc (a company listed on the NASDAQ, NASDAQ: NATR) from December 2009 to January 2018; and rejoined Fosun Pharma Group in March 2021 and is currently serving as the senior vice president of Fosun Pharma. Mr. Li served as a non-executive Director of the Company from October 2013 to January 2018 and served as a vice president and chief legal advisor of the Company from January 2018 to March 2021. Mr. Li once served as a director of Sinopharm (CNMC LTD) and Sinopharm Accord. Mr. Li has been a non-executive director of the Company since June 2021.